<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00465842</url>
  </required_header>
  <id_info>
    <org_study_id>JS0541</org_study_id>
    <secondary_id>NA_00037477</secondary_id>
    <nct_id>NCT00465842</nct_id>
  </id_info>
  <brief_title>Protein Biomarker in Hepatocellular Carcinoma</brief_title>
  <official_title>Protein Biomarkers for Early Detection and Prognostication in Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Singapore Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular carcinoma (HCC) is the fifth commonest cancer in the world with poor&#xD;
      prognosis, as the annual mortality is almost equivalent to the incidence. This is mainly due&#xD;
      to late diagnosis and co-morbid liver dysfunction. HCC is prevalent in our region than in the&#xD;
      West due to prevalent Hepatitis B infection and carriers. At the time of diagnosis, only 10 -&#xD;
      20% of HCC patients are candidates for liver resection or transplantation. Almost 40-50% of&#xD;
      patients have such poor liver function and co-morbid conditions that only supportive cares&#xD;
      are offered. Thus the median survival time is 18-24 months for resectable disease, 6 months&#xD;
      for unresectabe disease and 3 months for metastatic disease.&#xD;
&#xD;
      Current screening methods for HCC in high risk patients depend on alpha-fetoprotein (AFP) and&#xD;
      ultrasound of the liver. Neither test is sensitive or specific enough for early detection.&#xD;
      Therefore, early diagnosis with novel protein biomarkers is needed urgently and may provides&#xD;
      hope to improve treatment outcome.&#xD;
&#xD;
      Our preliminary study in 49 HCC patients have identified several proteins such as truncated&#xD;
      complement C3a, albumin, B2 microglobulin, may be potentially helpful in early diagnosis. We&#xD;
      have started a large prospective and longitudinal study in July 2006, with nearly 100&#xD;
      patients accrued. This application is to extend and expand our current study. We aim to (i)&#xD;
      identify and validate novel protein biomarkers for early diagnosis of HCC (ii) conduct&#xD;
      longitudinal proteomics with most up-to-date methods to discover new biomarker for early&#xD;
      detection and prognostication of HCC (iii) set up gene and plasma depository and clinical&#xD;
      database for HCC in collaboration with Singapore Tissue Network.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 40% of HCC patients have normal AFP. Moreover, AFP can also be elevated in patients&#xD;
      with cirrhosis or exacerbation of chronic hepatitis. Prospective studies evaluating the value&#xD;
      of AFP in HCC surveillance have reported sensitivities of 39-64%, specificity of 76-91% and&#xD;
      positive predictive values of 9 -32% 9-11.&#xD;
&#xD;
      Recently, a small handful of biomarkers were identified in the blood of 49 HCC patients by&#xD;
      SELDI / MS proteomic analysis of their blood with specificity and sensitivity both at 90% 12,&#xD;
      13. These were truncated complement C3a, albumin, B2 microglobulin, and histidine-rich&#xD;
      glycoprotein. In addition, insulin growth factor (IGF) and its binding protein have been&#xD;
      shown to be novel biomarkers of HCC 14-17. A larger prospective study is necessary to&#xD;
      validate these findings.&#xD;
&#xD;
      Other investigators have also used Surface-enhanced laser desorption / ionization&#xD;
      time-of-flight mass spectrometry (SELDI) to study proteomics in HCC. Most of the studies&#xD;
      included small numbers of patients and did not include independent test set or report on&#xD;
      reproducibility most of the time. Thus, controversies continue on both the technology of&#xD;
      SELDI and validation of the findings. Nevertheless, Ward et al reported that Kappa and Lumda&#xD;
      immunoglobulin light chains were elevated by an average pf 50% in the serum of HCC patients&#xD;
      (p &lt; 0.001, sensitivity 94%, specificity 86%) with Hepatitis C related cirrhosis 18.&#xD;
      Schwegler et al reported that SELDI-TOF MS profiling of serum can distinguish chronic&#xD;
      Hepatitis C from HCV- related HCC with a sensitivity of 61% and a specificity of 76%.&#xD;
      Sensitivity and specificity can be improved with the addition of AFP, des-gamma&#xD;
      carboxyprothrombin, and GP73 19. Other reports also indicated potential marker of heat-shock&#xD;
      protein 27 20 and complement C3a 21. However, all studies lack prospective and longitudinal&#xD;
      follow-up with multiple serum samples from same patient. Our trial is designed to test the&#xD;
      changes of proteomic overtime to identify the earliest possible biomarkers for HCC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Loss of funding due to difficulty with recruitment and participant retention.&#xD;
  </why_stopped>
  <start_date type="Actual">June 20, 2006</start_date>
  <completion_date type="Actual">August 14, 2013</completion_date>
  <primary_completion_date type="Actual">August 14, 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with presence of serum protein markers</measure>
    <time_frame>Day 1</time_frame>
    <description>Number of participants with truncated complement C3a, albumin, B2-microglobulin and histidine-rich glycoprotein, IGF-I, and IGF-II on first blood sample.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with hepatocellular carcinoma (HCC) with presence of protein markers.</measure>
    <time_frame>up to 5 years</time_frame>
    <description>To study the prospective and longitudinal value of these protein markers in detecting HCC by regular measurement of these proteins and follow up with routine clinical practice in high-risk patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with presence of serum protein markers with resectable and unrsectable HCC.</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Actual">211</enrollment>
  <condition>Normal Volunteers</condition>
  <condition>Hepatitis</condition>
  <condition>Liver Cirrhosis</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>A - Normal Volunteers</arm_group_label>
    <description>Normal volunteers without any history of liver disease and with normal liver functions test (LFT), including total protein/Albumin, LDH, ALT, AST, GGT, total bilirubin, direct and indirect bilirubin and do not belong to group B.&#xD;
Volunteers will be screened using questionnaires. Those deemed suitable will then be asked to have the blood test done. All blood tests are done free of charge to subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - Hepatitis B or C carriers with normal liver functions</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>C - Hepatitis B or C carriers with abnormal liver functions</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>D - Liver Cirrhosis</arm_group_label>
    <description>Liver cirrhosis, proven by liver biopsy or on clinical evidences, such as varices on CT scan indicative of portal hypertension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E - Hepatocellular Carcinoma (HCC) with Resection</arm_group_label>
    <description>HCC patients with resection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F - Unresectable HCC</arm_group_label>
    <description>Unresectable HCC patients with treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G - Malignant HCC</arm_group_label>
    <description>HCC patients with active malignant disease and only palliative care are offered.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        HCC patients, normal volunteers and patients with hepatitis with/without cirrhosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Group A: Normal volunteers without any history of liver disease and with normal liver&#xD;
             functions test (LFT), including total protein/Albumin, LDH, ALT, AST, GGT, total&#xD;
             bilirubin, direct and indirect bilirubin and do not belong to group B. Volunteers will&#xD;
             be screened using questionnaires. Those deemed suitable will then be asked to have the&#xD;
             blood test done. All blood tests are done free of charge to subjects.&#xD;
&#xD;
          -  Group B: Hepatitis B or C carriers with normal liver functions.&#xD;
&#xD;
          -  Group C: Hepatitis B or C carriers with abnormal liver functions.&#xD;
&#xD;
          -  Group D: Liver cirrhosis, proven by liver biopsy or on clinical evidences, such as&#xD;
             varices on CT scan indicative of portal hypertension.&#xD;
&#xD;
          -  Group E: HCC patients with resection.&#xD;
&#xD;
          -  Group F: Unresectable HCC patients with treatment.&#xD;
&#xD;
          -  Group G: HCC patients with active malignant disease and only palliative care are&#xD;
             offered.&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
             -â‰¥ 18 years of age&#xD;
&#xD;
          -  In this trial, diagnosis of HCC is established with either (a) known hepatitis B or C&#xD;
             carrier, and space occupying lesion(s) in the liver and AFP &gt; 400ng/ml or (b)&#xD;
             cytological or histological confirmation by biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        There is no exclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Singapore International Medical Center</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>April 23, 2007</study_first_submitted>
  <study_first_submitted_qc>April 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2007</study_first_posted>
  <last_update_submitted>February 12, 2019</last_update_submitted>
  <last_update_submitted_qc>February 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis</keyword>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>HCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

